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Abstract
Escherichia coli is a Gram-negative bacteria which is well known for its patho-
genic properties that can cause serious food poisoning, mostly indicated by diarrhea 
or other severe symptoms. Despite of its well-known properties due to its ability to 
produce toxin, most of E. coli strains are harmless and even beneficial especially in 
recombinant protein production. This bacterium is suitable for protein recombinant 
host since it has rapid growth, high expression rate, and well-known genome. 
Various proteins have been produced using E. coli expression systems, with thera-
peutic protein for medical application being the most notably produced. Apart from 
that, our group succeeded in producing beta galactosidase from a wild type E. coli 
strain B130. Furthermore, recombinant human serum albumin was successfully 
produced using E. coli strains BL21 (DE3). However, studies on E. coli toxin con-
tamination in recombinant protein productions, strains, and genomic comprehen-
sion are indispensable, particularly in therapeutic protein. Therefore, this chapter 
will discuss the safety aspects of recombinant therapeutic proteins in terms of toxin 
contamination by strain and genomic approaches.
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1. Introduction
Escherichia coli is a member of Enterobacteria family which can be found in 
gastrointestinal tracts [1–3]. In general, it is well known to cause broad diseases, 
including gastrointestinal problems. Aside the fact that E. coli was normal to be 
found in colon, a number of its strains were discovered with the ability to produce 
toxins. Shiga toxin E. coli (STEC) and enterotoxin E. coli (ETEC) were groups of 
E. coli strains that have the ability to produce toxin that may cause several diseases, 
such as diarrhea [1, 4, 5].
Although E. coli may cause numerous gastrointestinal diseases; in fact, strains 
that are responsible for pathogenic properties were relatively minor in numbers. 
Furthermore, E. coli was considered harmless and even useful as a host for pro-
ducing recombinant proteins. Even this bacteria becomes favorite host chosen in 
industrial and medical applications since it has rapid growth, well-characterized 
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gene, and its ability to grow under aerobic and anaerobic system, and facilitates to 
form high cell density culture (HCDC) [6–8].
The discussion about advantage in producing recombinant proteins and wor-
ries of toxins of E. coli is like talking about two opposite sides of a coin. This will 
certainly raise a question “Is it safe to produce recombinant protein in E. coli? Will 
it be toxin-free contamination?” Therefore, this chapter will discuss the safety 
aspects of recombinant protein produced by E. coli against toxins using genomic 
and strains approach.
2. Toxin produced by Escherichia coli
Several pathogenic E. coli strains are known to be responsible for broad diseases, 
from mild to complicated cases. It is varying from mild diarrhea, hemorrhagic 
colitis, to hemolytic uremic syndrome. Among the pathogenic strains, STEC is an 
example of common strains which occupy high number in E. coli serotypes that 
produce toxin called Shiga toxins (Stx) [1, 2, 5, 9–11]. While STEC is a common 
pathogenic example, it belongs to a larger group named enterohemorrhagic E. coli 
(EHEC); also, there still exist numerous pathogenic E. coli and cause different 
diseases and complications. Pathogenic E. coli were classified in Table 1 along with 
its diseases they caused and virulence factors [1].
Considering the number of pathogenic E. coli, it is useful to classify the toxins’ 
properties and structure. It will be convenience to determine whether the toxins 
belong to organic compound or peptide-based structure; therefore, we could ana-
lyze contamination probabilities in terms of producing recombinant protein. Most 
of the virulence factors stated in Table 1 were protein attached in bacterial mem-
brane with the role of adhesion or recognition to host cell [12]. Meanwhile, shiga 
toxin, heat-stable and heat-labile toxin, and other cytotoxins were protein released 
by pathogenic E. coli. These toxins have specific receptors to induce invagination to 
the host cell, while their virulence mechanism also differs depending on the nature 
of each toxin and their molecular target [4].
STEC serotypes vary and differ in number of incidences, although the O157:H7 is 
a serotype considered to be responsible of numerous outbreaks. Shiga toxin occupies 
AB5 structure (see Figure 1), the catalytic subunit A (StxA) and homopentamer of 
subunit B (Stx B) as recognition site to globotetraosylceramide (Gb3/Gb4), which 
are present in the host cell surface, which leads to invagination of the toxin. STEC 
can produce either Stx1 (Stx1 and Stx1c), Stx2 variant (Stx2, Stx2c, Stx2d, Stx2e, and 
Stx2f) or range combination of both variants [4, 12]. Once invagination succeeds, 
catalytic subunit A would disrupt cell metabolism by inhibiting elongation factor-
dependent aminoacyl tRNA binding (see detailed mechanism in [4]). The highly 
specific RNA N-glycosidase activity cleaves adenine base in eukaryotic ribosomal 
RNA, precisely at 28S subunit on the α-sarcin loop located in position 4324 [4].
Meanwhile, heat-labile (LT) and heat-stable (ST) toxin belong to ETEC 
groups. Nevertheless, LT enterotoxin shares similar structures to Stx which occupy 
AB5 conformation. Subunit A acts as a toxin by binding to its receptor, guanylyl 
cyclase C (GC-C). The interaction will activate guanine nucleotide protein Gsα 
by ADP-ribosylation, which trigger stimulation of secretion by cAMP-dependent 
mechanism. Elevated numbers of cAMP cause CTFR channel to secrete water and 
ions, thus generating diarrhea [3]. By contrast, ST structure is relatively simple. 
The STa class was made up with 18–19 cysteine-rich amino acids, while STb has 48 
amino acids. ST virulence acts by triggering secretion of water and ions by trigger-
ing signaling cascade through guanylyl cyclase C (GC-C) in intestine [13, 14]. The 
structure of both ST and LT is shown in Figure 2.
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Figure 1. 
Crystal structure of shiga-like toxin in E. coli (PDB: 1R4P). (A) Transversal view of Stx subunits, StxA 
represented as teal-colored chain, while StxB presented in rainbow color; (B) axial view of homopentamer 
StxB [3].
Pathogenic Diseases Virulence factors Reference
Enteric E. coli
[1]
Enteropathogenic E. coli 
(EPEC)
Diarrhea in 
children
Bfp, intimin, LEE
Enterohaemorrhagic E. 
coli (EHEC)
Hemorrhagic 
colitis, 
hemolytic 
uremic 
syndrome
Shiga toxins, intimin, Bfp
Enterotoxigenic E. coli 
(ETEC)
Traveler’s 
diarrhea
Heat-labile and heat-stable 
toxins, CFA
Enteroaggregative E. coli 
(EAEC)
Diarrhea in 
children
AAFs, cytotoxins
Enteroinvasive E. coli 
(EIEC)
Shigellosis-like Shiga toxin, hemolysin, 
cellular invasion, Ipa
Diffusely adherent E. coli 
(DAEC)
Acute diarrhea 
in children
Daa, AIDA
Adherent invasive E. coli 
(AIEC)
Crohn’s disease-
associated
Type 1 fimbriae, cellular 
invasion
Extraintestinal E. coli
Uropathogenic E. coli 
(UPEC)
Lower urinary 
tract infection 
and systemic 
infection
Type 1 and P fimbriae, AAFs, 
hemolysin
Neonatal meningitis E. 
coli (NMEC)
Neonatal 
meningitis
S fimbriae, K1 capsule
Avian pathogenic E. coli 
(APEC)
Food-borne 
source disease
Type 1 and P fimbriae, K1 
capsule
AAF, aggregative adhere fimbria; AIDA, adhesion involved in diffuse adherence; Bfp, bundle-forming pili; 
CFA, colonization factor antigen; Daa, diffuse adhesin; Ipa, invasion plasmid antigen; LEE, locus for enterocyte 
effacement.
Table 1. 
Classification of pathogenic E. coli.
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The fact both STEC and ETEC toxins (Stx and LT, and ST, respectively) are 
peptide based elucidates its origin that were genetically listed in their DNA. These 
toxins were made under central dogma of protein synthesis. Therefore, analysis 
through genomic approach on recombinant E. coli host is possible to be conducted.
3. E. coli as host for recombinant protein expression
The production of recombinant proteins in microbial systems was started in 1970 
and continued to boom in 1980 with the production of insulin. There is no doubt 
that this method has revolutionized and widened the field of biochemistry [19]. 
The ability to express large quantity of protein with less effort, relative to manual 
synthesis, allows industrial processes to produce in commercial scale. However, 
several considerations should be discussed before executing the production such 
as, appropriate vector, location of the protein of interest (whether as soluble frac-
tion or inclusion bodies), optimum condition (pH, medium, temperature, aerobic/
anaerobic system), genetic design for convenience of purification, and at the top of 
it, microbial selection [7, 8, 20].
E. coli become preferred microbes in terms of recombinant protein host among 
researchers and industrial use. The simplicity of its expression system, compared 
to other higher level organism, and large quantity of well-characterized genomic 
database offer advantages in constructing the vector to be used [20]. A plenty 
number of research regarding E. coli also become an advantage to give amount of 
consideration of various expression conditions. Nevertheless, E. coli expression 
system has limited post-translational modification, which means that some proteins 
that require modification, such as alkylation or glycosylation, may not be perfectly 
expressed in E. coli. However, several strains of E. coli have the ability to perform 
specific post-translational modification [19, 21]. Therefore, we provide a simple 
summary on recombinant proteins produced by E. coli along with strains and 
expression strategies in Table 2.
Among recombinant proteins mentioned in Table 2, hEGF and hPT-2 are examples 
of therapeutic protein. Regarding its use in medical interests, therapeutic proteins 
produced in E. coli have to be safe for administration into human bodies; therefore, 
purification steps and any contaminants present become a huge concern in producing 
recombinant protein. Idetifying location of protein target is a prominent fundamental 
to determine source of contamination and to predict any possible contamination. 
Understanding the protein location also helps with the purification strategies needed 
to separate contaminants, specifically toxins, with the result that highly pure pro-
teins were recovered. Choi et al. [29] through Figure 3 classify locations of protein 
expressed in E. coli and its general purification steps needed.
Figure 2. 
Enterotoxin secreted by ETEC. (A) Heat-labile enterotoxin (PDB: 1tii) [16]; (B) heat-stable enterotoxin, STa 
class (1etn) [17]; (C) heat-stable enterotoxin, STb class (1ehs) [18].
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The distinction of protein location is affected by either the nature of the expres-
sion system or the protein construction design. Both extracellular and intracel-
lular strategies on expressing protein give its own advantages and disadvantages. 
Extracellular expression offers simple purification, improved folding, and soluble 
products. This strategy can be achieved using signal peptide, co-expression with 
phospholipase, or co-expression with chaperon [33, 34]. In contrast, intracellular 
expression prefers inclusion bodies formation. While inclusion bodies give easy 
separation and prevent protease degradation, it has complex purification steps and 
refolding process is compulsory. Fusion partners, such as intein, often added in gene 
construction in intracellular works to provide efficient strategy in purification steps 
[21, 33].
Based on protein location, toxin contamination can be investigated. Both Stx and 
LT-ST toxins are secreted by E. coli, increasing the risk of contamination when the 
protein of interest is produced extracellularly. Even so, since extracellular protein 
exists in soluble state, purification might not be impossible. Whereas intracellular 
expression may put more concern at contamination risk since toxins might be 
clumped together in the form of inclusion bodies. This case may put more consider-
ation in solubilization and purification process. However, these allegations are only 
an assessment of risk factors with the assumption that toxins are produced in E. coli, 
which is used for recombinant protein expression.
Recombinant proteins Strain Expression strategies Ref.
α-Cyclodextrin 
glycosyltransferase
BL21 (DE3) Extracellular, using OmpA 
constructed on pET-20b(+) 
vector
[22]
P64k E. coli K12 GC366 Soluble intracellular, using 
pM-152 vector
[23]
SpA-βgal (Staphylococcus protein 
A-E. coli β-galactosidase)
E. coli RR1 LacZ Soluble intracellular as fusion 
protein
[24]
Human prethrombin-2 (hPT-2) E. coli TOP10F’ Fusion protein with intein, 
CBD-Ssp DnaB-hPT-2
[25]
Human prethrombine-2 (hPT-2) E. coli BL21 (DE3) 
ArcticExpress
Soluble intracellular using 
pTWIN1
[26]
Human epidermal growth factor 
(hEGF)
E. coli BL21 (DE3) Extracellular using TorA signal 
peptide constructed on pD881 
vector
[6]
Human epidermal growth factor 
(hEGF)
E. coli BL21 (DE3) Extracellular, using OmpA 
constructed in pD881 vector
[27]
Human serum albumin E. coli BL21 (DE3) Extracellular, using TorA 
constructed on pD881 vector
[28]
Pyrococcus furiosus α-amylase 
(PFA)
E. coli DH5α Soluble protein, designed with 
co-expression of prefoldin, 
chaperonin HSP60, and sHSP
[29]
Hepcidin E. coli BL21 (DE3) Inclusion bodies, fused with 
His-tag
[30]
Keratinase E. coli AD494(DE3)
pLys
Intracellular expression using 
His-tag
[31]
Pig liver esterase (γ-PLE) E. coli origami 
(DE3)
Soluble intracellular, using 
Strep-tag and combination of 
His- and Trx-tag
[32]
Table 2. 
Summary of recombinant protein using E. coli expression system and its expression strategy.
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4. Safety aspects of recombinant protein production against toxin
Using comprehensive understanding of toxin origin, specifically Shiga toxin 
and enterotoxin, it is clear that these toxins were peptide based and generated by 
certain gene in STEC and ETEC. The gene stx was responsible for producing the 
Stx toxin using central dogma of E. coli, reciprocally to ST and LT encoding gene. 
Moreover, E. coli strains that are commonly used for recombinant protein work are 
also known. Therefore, it is possible to examine the safety aspect of recombinant 
protein against toxin through genetic alignment between common E. coli strains in 
recombinant work and toxin genes. Here, E. coli BL21 (DE3) (ACC: NC_012892) 
and K-12 MG1655 (ACC: U00096.3) were used as representative. While toxin genes 
used are Stx (ACC: AY143336.1), LT (ACC: JQ031712), and ST (ACC: P22542.1).
In term of the existence of stx gene, common recombinant host strains are absence 
of the stx gene. Therefore, since the strains were clearly different, it is considerably 
safe to use E. coli as recombinant host without neglecting other contaminants.
5. Expression and characterization of HSA gene in E. coli BL21 (DE3)
This step started with growing E. coli BL21 (DE3) [pD881-torA-HSA] transfor-
mant as starter culture at 200 rpm, 37°C for 16–18 hours. Then starter culture was 
moved as much as 1% into 25 mL Luria-Bertani medium containing kanamycin as 
selection marker. E. coli BL21 (DE3) cell culture was grown until OD600nm reached 
0.8 for induction. Before induction was performed, 1 mL sample from culture 
was separated as protein fraction before induction (t0). Induction was initiated by 
adding L-rhamnose into the expression medium to bring the final concentration to 
4 mM. To obtain protein fraction in cytoplasm, sonication method was used. Lysate 
from six E. coli BL21 (DE3) [pD881-torA-HSA] transformant colonies showed 
that HSA was expressed in cytoplasm, it was characterized with the presence of 
±67.0 kDa and in the SDS-PAGE electrophoresis [28]. The result of expression is 
presented in Figure 4.
Figure 3. 
Scheme of protein expressed in E. coli and its following purification steps [33].
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6. Recombinant hEGF expression in E. coli BL21 (DE3)
E. coli BL21 (DE3) [pD881-PelB] that has been characterized was grown in 5 mL 
LB medium containing kanamycin for about 16–18 hours at 37°C with 200 rpm 
shaking. Then, 1000 μL E. coli BL21 (DE3) [pD881-PelB] culture was transferred 
into 100 mL LB medium containing kanamycin in shaken flask. Native E. coli BL21 
(DE3) was also grown and received the same treatment as the transformant. The 
culture was incubated until OD600nm reached 0.7. E. coli BL21 (DE3) [pD881-PelB] 
culture was taken as a sample (before L-Rhamnose induction) and transferred into 
a microtube and centrifuged at 3000 g, 4°C for 20 minutes. L-rhamnose was added 
into E. coli BL21 (DE3) [pD881-PelB] and native E. coli BL21 (DE3) culture to give 
final concentration of 2 mM. Incubation was continued at 37°C for 20 hours with 
200 rpm shaking. Culture of the E. coli BL21 (DE3) [pD881-PelB] was taken as a 
sample (after L-rhamnose induction) and transferred into 2 microtubes then was 
centrifuged at 3000 g, 4°C for 20 minutes [35].
Figure 4. 
SDS-PAGE electropherogram of HSA soluble fraction in cytoplasm after induction using 4 mM L-rhamnose 
from E. coli BL21 (DE3) [pD881-torA-HSA] colonies. (M) Protein marker; (t0) fraction before L-rhamnose 
induction; (Ki) colony transformant 1–6 after induction L-rhamnose induction [28].
Figure 5. 
Electropherogram of proteins expressed by E. coli BL21 (DE3) [pD881-PelB] with varying L-rhamnose 
concentration. Lane M is the protein markers. Lane (a-e) are soluble fractions of the medium with 40 μM, 
1 mM, 2 mM, 4 mM, and 6 mM L-rhamnose as inducer, respectively. While lane (f-i) are inclusion bodies 
obtained from cell with 1 mM, 2 mM, 4 mM and 6 mM L-rhamnose as inducer. Samples were collected after 
20 hours of induction [35].
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Based on SDS-PAGE electrophoresis of the protein produced by the E. coli cell 
at varying concentration of L-rhamnose as inducer (Figure 5), it can be concluded 
that the best concentration of L-rhamnose that induces the production of the 
protein of interest was 4 mM because it produces more target protein, either in 
the insoluble fraction of the medium or in the form of inclusion bodies at t(20). The 
results also indicate that not all rhEGF translocated into the periplasm were secreted 
to medium. The hEGF was expressed in E. coli BL21 (DE3) with molecular weight of 
6.2 kDa. The result of expression is presented in Figure 5 [35].
Apart from that, our group succeeded in producing beta-galactosidase from a 
wild type E. coli strain B130, with high purity. Kinetical parameter (Km and Vmax) of 
the enzyme were 2.417 × 10−4 mol and 4.664 × 10−4 mol.minute−1, respectively [36].
7. Conclusions
E. coli is renowned by its pathogenic properties, specifically in causing gastroin-
testinal disease. While in contrast, the same species also being helpful in expressing 
recombinant protein. Thus, contrary properties leave questions in terms of safety in 
expressing recombinant protein. Pathogenic E. coli strains were identified and clas-
sified in accordance with the disease caused. While most of pathogenic group gain 
its virulence by their membrane protein, some of it secretes toxins, like Stx from 
STEC or LT and ST from ETEC group. This toxin-secreting E. coli were important 
to understand contamination risk in recombinant protein. All three toxins were 
considered as peptide-based structure, in which production relies on respective 
genes. Alignment of toxin genes to commonly used E. coli in recombinant work 
makes a way to investigate toxin presence in recombinant-host E. coli. The BL21 
(DE3) and K-12 MG1655 strains used as representative in alignment process, which 
generate non-overlapping alignment. This clears up the risk of toxin contamination 
on recombinant protein since the absence of toxin gene in these strains. Therefore, 
expressing recombinant protein, especially therapeutic protein, in E. coli was 
considered to be safe against toxin.
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